Active	Status	Sponsor type	Region	Phase	Filter
4 Active 7 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
blarcamesine (Anavex 2-73) / Anavex
2021-004325-80: ANAVEX2-73 Extension Study for treatment in AD Extensie studie met ANAVEX2-73 voor de behandeling van AD	Not yet recruiting	2/3	325	Europe	ANAVEX2-73, ANAVEX2-73, Capsule, Oral solution	Anavex Germany GmbH, Anavex Germany GmbH	Alzheimer's Disease Ziekte van Alzheimer, Dementia Dementie, Diseases [C] - Nervous System Diseases [C10]
2019-003302-27: ANAVEX2-73 used for a new treatment in AD	Not yet recruiting	2/3	509	Europe	ANAVEX2-73, ANAVEX2-73, Capsule	Anavex Germany GmbH, ANAVEX Life Sciences Corp., Anavex Germany GmbH, ANAVEX Life Sciences Corp.	Alzheimer's Disease, Alzheimer's Disease, Diseases [C] - Nervous System Diseases [C10]
EXCELLENCE, NCT04304482: ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome	Completed	2/3	92	Europe, Canada, RoW	ANAVEX2-73 oral liquid, Blarcamesine, Placebo oral liquid	Anavex Life Sciences Corp., Anavex Australia Pty Ltd., Anavex Germany GmbH	Rett Syndrome	06/23	06/23
ATTENTION-AD, NCT04314934: OLE of Phase 2b/3 Study ANAVEX2-73-AD-004	Completed	2/3	300	Europe, Canada, RoW	ANAVEX2-73, Blarcamesine	Anavex Life Sciences Corp., Anavex Australia Pty Ltd., Anavex Germany GmbH	Alzheimer Disease	06/24	06/24